The present invention is directed to devices for occluding lumens within a body and, more particularly, directed to devices employing an expansile frame associated with an expansile plug and methods for use and manufacturing of such devices.
It is often necessary to close a blood vessel, lumen, duct, aneurysm, hole, fistula, or appendage, referred to herein collectively as a lumen, within a body. For example, under certain circumstances the optimum treatment for an aneurysm is to occlude the vessel that feeds blood into the lesion. In the neurovascular anatomy, this vessel may be the carotid artery, or in the peripheral vasculature, it may be an iliac artery. Additional examples include: a patent ductus arteriosus (PDA) which shunts blood from the aorta to the pulmonary artery in some newborn babies; a patent foramen ovale (PFO), an open flap in the septum separating the heart's atria; a blood vessel feeding a tumor; an atrial septal defect (ASD), a hole in the septum between the atria; an iliac artery in conjunction with a stent graft and a femoral-femoral bypass operation the closure of which provides treatment of an aortic aneurysm; an atrial appendage, which is a malformation that allows blood clots to collect, which, in turn, may cause a stroke. Furthermore, there are various types of fistula in which organs are improperly connected together such as colovaginal fistula, oromaxillary fistula, and arteriovenous malformation (AVM).
There are numerous devices in the prior art that may be used to close or otherwise occlude these lumens. One such device is a detachable balloon which is inflated in the target lumen with a liquid or polymer, then detached and maintained at or in the target. Another device is a basket-like structure formed of wires that causes clots in the blood flow thereby blocking a blood vessel. Another device is a coil or hydrogel coated coil that is deployed in a lumen. Another device is a self-expanding patch that blocks a PFO or ASD from both sides. Further examples include plugs, beads, or particles made from hydrogel or polyvinyl alcohol (PVA) that may expand upon blood contact and serve to occlude or block a lumen.
There is, however, an ongoing need to provide a more advanced and improved device for occluding lumens that is easier to place, requires fewer steps for deployment, and has a lower tendency to migrate after placement.
One embodiment according to the present invention includes an occlusion device in which the support structure or frame expands circumferentially within the lumen to secure an expansile plug or embolic material. Once in place, the expansile plug or embolic material expands, thereby occluding the target lumen.
Another embodiment according to the present invention includes a radially expandable support structure having a closed portion for capturing subsequently delivered embolic material, such as embolic coils. For example, the structure may have a closed portion at its distal end or at its middle (forming an hourglass shape). Additionally, the closed portion may be formed from the support structure itself or from a discrete, second layer that is attached within the support structure.
The occlusion devices of the present invention can be useful in multiple medical fields such as radiology, gastroenterology, gynecology, cardiology, neurovascular intervention, and oncology.
These and other aspects, features, and advantages of which embodiments of the invention are capable of will be apparent and elucidated from the following description of embodiments of the present invention, reference being made to the accompanying drawings, in which
Specific embodiments of the invention will now be described with reference to the accompanying drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. The terminology used in the detailed description of the embodiments illustrated in the accompanying drawings is not intended to be limiting of the invention. In the drawings, like numbers refer to like elements.
The embodiments of the present invention are generally directed to lumen occlusion devices having an expandable framework. As described in more detail below, the framework may have an attached, expansile plug or may be filled with embolic material after deployment.
The frame 14 has a proximal end portion 18 and a distal end portion 20 that are outwardly flared. Alternatively stated, the proximal end portion 18 and the distal end portion 20 employ projecting elements 22 extending radially outward. In certain embodiments, the projecting elements 22 take the form of loops, hooks, protuberances, or staples, which tend to increase the friction between the frame and the lumen. These projecting elements 22 tend to hold the frame 14 in place in conjunction with the frame's 14 radial force. This feature is especially useful when the area or lumen to be obstructed is relatively short, which reduces the aggregate radial force of the frame 14 compared to a longer lumen, or where there is high flow such as an iliac or carotid artery.
In certain embodiments, a variety of radiopaque markers such as marker bands, coils, and plating, not shown, are connected to the frame 14. For example, markers can be located at the ends of the projecting elements 22, near the plug 12, and/or along a length of the frame 14 to assist the operator with visualization, guidance and delivery of the device 10 during deployment.
Formation of the relaxed or minimum energy state configuration of shape memory structures such as the device 10 described herein are well known in the art. For example, the relaxed or minimum energy state configuration of the frame 14 is formed by weaving, winding, or otherwise manipulating the wire 16 about a fixture. Once the desired form is achieved for the frame 14, the frame 14 is subjected to a heat treatment. For example, the frame 14 is maintained at a temperature of about 500 degrees Celsius to about 1000 degrees Celsius for approximately 30 to 90 minutes. Following the heat treatment, the frame 14 is cooled to room temperature and ultrasonically cleaned. The resultant secondary configuration is thereby made permanent and becomes the relaxed or minimum energy state configuration of the device 10.
In one embodiment, the frame 14 is formed of a plurality of the same or a combination of different wires 18. For example, the wire 16 may be formed of Nitinol, steel, chromium-cobalt alloy, and/or platinum, and/or of polymers such as Teflon, polyethylene terephthalate (PET), or polyether ether ketone (PEEK).
In one embodiment, the frame 14 can be any of the stents seen in U.S. application Ser. No. 13/003,277 filed Jan. 7, 2011 and U.S. application Ser. No. 13/311,430 filed Dec. 5, 2011, the contents of which are hereby incorporated by reference.
The plug 12 is formed of, for example, hydrogel or other similar expansile material such as PVA or hydrogel foam. As shown in
The plug 12 can be constructed from a variety of known polymeric materials including, for example, biocompatible, macroporous or microporous, hydrophilic or hydrophobic hydrogel foam materials. Suitable materials are described in U.S. Pat. No. 6,165,193 to Greene Jr. et al. and U.S. Pat. No. 6,878,384 to Cruise et al., each of which is hereby incorporated by reference. The plug 12 may also comprise polymers such as polyvinyl alcohol foams as described in U.S. Pat. No. 5,823,198 to Jones et al., which is also incorporated herein by reference.
In another embodiment of the present invention, the plug 12 is made of a biocompatible, macroporous, hydrophilic hydrogel foam material, in particular a water-swellable foam matrix formed as a macroporous solid comprising a foam stabilizing agent and a polymer or copolymer of a free radical polymerizable hydrophilic olefin monomer cross-linked with up to about 10% by weight of a multiolefin-functional cross-linking agent. A suitable material of this type is described in U.S. Pat. No. 5,750,585 to Park et al., the disclosure of which is incorporated herein by reference. Another suitable material is a porous hydrated polyvinyl alcohol foam (PAF) gel prepared from a polyvinyl alcohol solution in a mixed solvent consisting of water and a water-miscible organic solvent, as described, for example, in U.S. Pat. No. 4,663,358 to Hyon et al., the disclosure of which is incorporated herein by reference. Still another suitable material is PHEMA, as discussed in U.S. Pat. No. 4,663,358 to Hyon et al., “Hydrolysed Microspheres from Cross-Linked Polymethyl Methacrylate”, J. Neuroradiol., Vol. 18, pp. 61-69 (1991), both of which are hereby incorporated by reference.
It may be desirable to reduce the size of the plug 12 for the purpose of performing percutaneous procedures. This may be done mechanically by using a fixture to compress the plug, chemically by dehydrating the polymer with an agent such as alcohol, or through a combination of these methods. I
In certain embodiments of the present invention, the plug 12 may incorporate radiopaque elements, for example, iodine or tantalum powder, mixed into the material forming the plug 12 during manufacturing to help visualize the location of the plug 12 and the device 10 before and after deployment.
The plug 12 is preferably associated with or otherwise attached to the frame 14 by a thread 24. The thread 24 is formed of, for example, polyethylene terephthalate (PET) having a diameter of approximately 0.0009 inches. One end of the thread 24 is skewered or otherwise passed through a portion of the plug 12 and around the wire 16 of the frame 14 and then fixed to a second end of the thread 24 so as to form a loop. A plurality of threads 24 may also be employed to secure the plug 12 to the frame 14 at the same or at different locations along a dimension of the frame 14.
In certain embodiments, the plug 12 is associated with the frame 14 by employing a thread 24 formed of polypropylene or olefin elastomer such as Engage. Still in other embodiments, the plug 12 is associated with the frame 14 by mechanical methods such as: constructing the frame 14 in the shape of a cage or basket that holds the plug 12 within; directly skewering an element of the frame 14, such as a portion of the wire 16, through the plug 12; gluing the plug to the frame 14; incorporating mechanical grasping elements into the frame 14 to hold the plug 12; or using heat-shrinkable plastic to hold the plug 12 to the frame 14.
After the frame 14 and plug 12 have been associated, the device 10 can be loaded into a delivery device such as a catheter or sheath. In a more specific example, the device 10 can be compressed on an inner pusher member that is located within a retractable sheath. In one example, the delivery device has a size of about 4 French for delivery into a lumen or vessel between about 2-4 millimeters in diameter.
One or more plugs 12 are attached at the narrow, center portion of the frame 102 as described in previous embodiments, for example by employing threads 24. Alternatively, one or more plugs 12 may be anchored to the frame 102 by skewering the plugs 12 with the frame 102. Radiopaque markers, not shown, may also be employed as previously described regarding the device 10. The device 100 is at least partially linearized (i.e., the coil shape is at least partially uncoiled into a generally linear shape) for delivery via a delivery catheter and deployed.
The device 100 is especially useful for closing lumens that have large diameters relative to their lengths and lumens in which a treatment device is subjected to forces from multiple directions. Examples of these types of lumens are ASD, PFO, and PDA's. The device 100 is useful in occluding these lumens because the distal end of the frame 102 can be placed on one side of the lumen (i.e. in the atrium or pulmonary artery), the plug 12 positioned substantially within the lumen, and the proximal end on the other side of the lumen. Since the frame 102 tends to revert to its original substantially helical configuration, it tends to exert force on both sides of the septum or ductus, thus sandwiching the plug in the lumen.
In another embodiment of the present invention, as shown in
In another embodiment, as shown in
In yet another embodiment, one or both ends of the frame are at least partially closed or covered with, for example, a mesh, crossing or interwoven threads, or fabric. This covering can be attached over either open or closed ends of the frame and prevents the plug 12 from migrating away from the frame and target.
In one embodiment, as shown in
The wires 114 can be radially oriented in a uniform spacing, such as approximately 120 degrees apart, or in any variety of symmetrical and asymmetrical, non-uniform spacing, such as 100, 130, 130 degrees. In one example configuration, the wires 114 are composed of a shape memory material such as Nitinol, have a diameter of about 0.003 inches, and have ends that are capped with radiopaque markers 120. Alternatively, the wires 114 may be formed by laser cutting a hypotube to the desired dimensions of the wire 114.
The device 110 is particularly useful for closing a PDA. The device 110 can be collapsed into a delivery system and delivered to a target site by conventional means. In one example, the plug 12 expands to a dimension of about 0.185 inches after deployment and closes off or otherwise seals the target site (e.g., a PDA). The expanded and radially curved wires 114 are preferably deployed on either side of the defect and thereby provide support for the plug 12 so as to prevent migration. It should be noted that the device 110 may include any number of wires 114, but preferably between at least 2 and 20 wires, and more preferably at least 3-6 wires. Advantageously, the device 110 is relatively simple to construct and tends to have a smaller delivery profile as compared with many other device shapes.
While the previously described embodiments have included the use of an expandable plug 12, it is also possible to use one or more of these devices without a plug 12. More specifically, a material can be added upstream or adjacent to the deployed device so as to cause the blockage. For example, one or more embolic coils (which may or may not include an expandable material such as hydrogel), can be delivered within the deployed and expanded device.
Once the device 142 is deployed at a target occlusion location, a second delivery catheter 141 (or possibly the same delivery catheter) is advanced to the proximal end 146 of the device 142 and embolic material is deployed into the proximal half of the device 142. In this example, the embolic material is one or more embolic coils 168. These embolic coils 168 may include an expansile coating (such as hydrogel) that expands within a patient's blood or may include expansile material that is separate from the coils 168. In this respect, half of the device 142 is filled with material, thereby occluding most of the blood flow through the lumen 152. Over time, this occlusion will likely become completely blocked by expansion of any expansile coating on the embolic coils 168, clotting of the blood and/or tissue growth over the embolic coils 168.
As with the previous embodiment, the device 162 is delivered to a desired occlusion point in a lumen 152. Next, the distal end of the delivery catheter 141 is positioned adjacent or even partially inside of the framework 162 and the embolic coils 168 are deployed within the device 160. Since the downstream or distal end 164 of the frame 162 is closed to act as a stable barrier, the embolic coil 168 is prevented from migrating downstream through the lumen 152, thus occluding the lumen 152. Again, other embolic materials, such as hydrogel, may be used in conjunction with device 160 and embolic coils 168.
Alternately, both ends of the device 162 may be closed and the embolic material, such as embolic coils 168 can be delivered inside a cavity of the device, through apertures in the weaving. For example, an embolic coil deliver catheter can be inserted through an aperture created by its woven wires and the embolic coil can be advance into the device 162.
Preferably, occluding material, such as embolic coils 168 can be delivered into the proximal end 176 of the device 170 to occlude the lumen 152. The inner stent layer 180 may be coated in an expansile material, such as hydrogel, in addition to or in place of the discretely-added occluding material.
The outer, anchoring stent layer 172 is preferably composed of one or more wires having a larger diameter than those composing the inner, occluding stent layer 180. Additionally, the outer layer 172 can be woven to have apertures that are larger than those of the inner stent layer 180, when both layers are in an expanded configuration. In this respect, the outer layer 172 can provide relatively more radially outward force for anchoring while the inner layer 180 can provide a relatively finer-woven occlusive barrier.
Preferably, the inner stent layer 180 is connected to the outer stent layer 172 at its proximal end and optionally at its distal end. Additionally, the inner stent layer 180 can be located near the outer stent layer's proximal end 176, distal end 174, middle, or any positions therebetween.
The device 170 has several advantages compared to prior art lumen obstruction devices that occlude a lumen by preventing dislodgement of embolization coils, The present invention allows partial deployment of re-sheathing due to its attachment mechanism, allowing for a more controlled placement of the device. Further, the present invention can be used with much smaller catheters, conceivably down to 1.7 French compared to a 5 French or greater sized catheter. This allows the present invention to navigate more tortuous and distal lumens, thereby being able to treat a wider range of patients. Additionally, this allows the same catheter to be used to deliver both the device and the embolic coils and materials. Further, the present invention minimizes any trauma imposed on the lumen wall by using a self-expanding radial force tuned for the artery size.
The previously described device, such as 140, 160, and 170, can be made with a variety of materials including, but not limited to bioactive, thrombogenic, hydrogel, or other therapeutic coatings. Further, these devices can be made in a variety of different sizes and lengths and can be cinched or enclosed at any location along the length of the stent. To improve clinical outcomes, the device can be coated with, for example, bioactive or hydrogel coatings. The device can be used with varying porosities to provide full or partial flow occlusion to limit the amount of embolic materials required to sufficiently occlude a lumen.
Delivery of the above described devices can be accomplished using various delivery systems. For example, the device can be delivered by pushing the device through a catheter or sheath with a specialized pusher or a guidewire by attaching one or both ends of the device to a delivery pusher that holds the device so that it can be positioned and repositioned within the lumen. The device is then selectively detached from the delivery system by, for example, mechanically, thermally, hydraulically, or electrolytically severing an attachment member associating the device and the delivery system.
In one embodiment, the device incorporates at least one radiopaque marker band positioned at one end of the device. The marker is configured to interlock to a mating element on a delivery pusher. The user can partially deploy and retrieve the device using the interlock to pull back on the device. Release of the device from the delivery system is, for example, accomplished by pushing most of the implant out of the delivery catheter and/or retracting the delivery catheter to expose the interlock release(s).
In another embodiment, a monofilament is wrapped through the proximal end of the device and then attached to a delivery pusher incorporating a heater that can be activated by electrical current. The user can fully or partially deploy the device and then reposition or recover the device if needed. When the device is in the desired location, the user activates the heater thereby causing the monofilament to break from and release the device.
In yet another embodiment, one end of the device incorporates an atraumatic tip while the other end is soldered to a delivery pusher. The user can deploy and reposition the device as needed, and then pass a current through the delivery pusher. The current causes the solder to corrode at an accelerated rate in the patient's blood and to release the end of the device that was soldered to the pusher.
Alternatively, the end of the device incorporates a coupling element such as a tube of radiopaque material that is configured to allow a heat-severable thread having two ends to pass through the coupling. One end of the thread is tied to the device and the other end of the thread is passed through a heater incorporated into the end of a delivery pusher. The device is detached by the user as previously described.
In another embodiment, the delivery system includes a sheath disposed over a pusher member. A stent device is compressed over a distal end of the pusher and the sheath is placed over the stent. In this respect, the stent is maintained in place, in part, via frictional forces. Additional details of such a delivery system can be found in U.S. application Ser. No. 13/003,277 filed Jan. 7, 2011 and U.S. application Ser. No. 13/311,430 filed Dec. 5, 2011, both of which were previously incorporated by reference in this specification.
The present device and method has several advantages over the prior art. In comparison to prior art detachable balloons, the device of the present invention is easier to place, requires fewer steps to deploy, and has a lower tendency to migrate after placement if, for example, a balloon-based device starts to leak over time.
Although the invention has been described in terms of particular embodiments and applications, one of ordinary skill in the art, in light of this teaching, can generate additional embodiments and modifications without departing from the spirit of or exceeding the scope of the claimed invention. Accordingly, it is to be understood that the drawings and descriptions herein are proffered by way of example to facilitate comprehension of the invention and should not be construed to limit the scope thereof.
This application claims priority to U.S. Provisional Patent Application Ser. No. 61/485,065 filed May 11, 2011 entitled Device for Occluding A Lumen, the entirety of which is incorporated by reference herein.
Number | Name | Date | Kind |
---|---|---|---|
3868956 | Alfidi | Mar 1975 | A |
4130904 | Whalen | Dec 1978 | A |
4140126 | Choudhury | Feb 1979 | A |
4286341 | Greer et al. | Sep 1981 | A |
4512338 | Balko et al. | Apr 1985 | A |
4553545 | Maass et al. | Nov 1985 | A |
4562596 | Kornberg | Jan 1986 | A |
4577631 | Kreamer | Mar 1986 | A |
4655771 | Wallsten | Apr 1987 | A |
4663358 | Hyon et al. | May 1987 | A |
4733665 | Palmaz | Mar 1988 | A |
4734097 | Tanabe et al. | Mar 1988 | A |
4740207 | Kreamer | Apr 1988 | A |
4768507 | Fischell et al. | Sep 1988 | A |
4800882 | Gianturco | Jan 1989 | A |
4852568 | Kensey | Aug 1989 | A |
4856516 | Hillstead | Aug 1989 | A |
4941870 | Okada et al. | Jul 1990 | A |
4990582 | Salamone | Feb 1991 | A |
4994069 | Ritchart et al. | Feb 1991 | A |
5015253 | MacGregor | May 1991 | A |
5019090 | Pinchuk | May 1991 | A |
5026377 | Burton et al. | Jun 1991 | A |
5035706 | Giantureo et al. | Jul 1991 | A |
5041126 | Gianturco | Aug 1991 | A |
5041292 | Feijen | Aug 1991 | A |
5078726 | Kreamer | Jan 1992 | A |
5084065 | Weldon et al. | Jan 1992 | A |
5116365 | Hillstead | May 1992 | A |
5133731 | Butler et al. | Jul 1992 | A |
5135536 | Hillstead | Aug 1992 | A |
5158548 | Lau et al. | Oct 1992 | A |
5162430 | Rhee et al. | Nov 1992 | A |
5171262 | MacGregor | Dec 1992 | A |
5192297 | Hull | Mar 1993 | A |
5197978 | Hess | Mar 1993 | A |
5226911 | Chee et al. | Jul 1993 | A |
5234456 | Silvestrini | Aug 1993 | A |
5256146 | Andrews | Oct 1993 | A |
5258042 | Mehta | Nov 1993 | A |
5304200 | Spaulding | Apr 1994 | A |
5312415 | Palermo | May 1994 | A |
5314444 | Gianturco | May 1994 | A |
5342300 | Stefanadis | Aug 1994 | A |
5382259 | Phelps et al. | Jan 1995 | A |
5382260 | Dormandy, Jr. et al. | Jan 1995 | A |
5383887 | Nadal | Jan 1995 | A |
5389106 | Tower | Feb 1995 | A |
5395390 | Simon et al. | Mar 1995 | A |
5405377 | Cragg | Apr 1995 | A |
5410016 | Hubbell et al. | Apr 1995 | A |
5415664 | Pinchuk | May 1995 | A |
D359802 | Fontaine | Jun 1995 | S |
5433723 | Lindenberg et al. | Jul 1995 | A |
5464449 | Fogarty | Nov 1995 | A |
5476472 | Dormandy, Jr. et al. | Dec 1995 | A |
5476505 | Limon | Dec 1995 | A |
5480423 | Ravenscroft et al. | Jan 1996 | A |
5484449 | Amundson et al. | Jan 1996 | A |
5514379 | Weissleder et al. | May 1996 | A |
5514380 | Song et al. | May 1996 | A |
5536274 | Neuss | Jul 1996 | A |
5540701 | Erlich | Jul 1996 | A |
5554190 | Draenert | Sep 1996 | A |
5558633 | Phipps et al. | Sep 1996 | A |
5578074 | Mirigian | Nov 1996 | A |
5582619 | Ken | Dec 1996 | A |
5607445 | Summers | Mar 1997 | A |
5609627 | Goicoechea et al. | Mar 1997 | A |
5609628 | Keranen | Mar 1997 | A |
5609629 | Fearnot et al. | Mar 1997 | A |
5613981 | Boyle et al. | Mar 1997 | A |
5624461 | Mariant | Apr 1997 | A |
5630829 | Lauterjung | May 1997 | A |
5645558 | Horton | Jul 1997 | A |
5658308 | Snyder | Aug 1997 | A |
5674241 | Bley et al. | Oct 1997 | A |
5674276 | Andersen et al. | Oct 1997 | A |
5674295 | Ray et al. | Oct 1997 | A |
5702418 | Ravenscroft | Dec 1997 | A |
5716410 | Wang et al. | Feb 1998 | A |
5718711 | Berenstein et al. | Feb 1998 | A |
5741325 | Chaikof et al. | Apr 1998 | A |
5749894 | Engelson | May 1998 | A |
5750585 | Park et al. | May 1998 | A |
5769882 | Fogarty et al. | Jun 1998 | A |
5785679 | Abolfathi et al. | Jul 1998 | A |
5785965 | Pratt et al. | Jul 1998 | A |
5800454 | Jacobsen et al. | Sep 1998 | A |
5823198 | Jones et al. | Oct 1998 | A |
5843089 | Sahatjian et al. | Dec 1998 | A |
5898062 | Allcock et al. | Apr 1999 | A |
5911717 | Jacobsen et al. | Jun 1999 | A |
5911731 | Pham et al. | Jun 1999 | A |
5919224 | Thompson et al. | Jul 1999 | A |
5935148 | Villar et al. | Aug 1999 | A |
5941249 | Maynard | Aug 1999 | A |
5951599 | McCrory | Sep 1999 | A |
5980514 | Kupiecki et al. | Nov 1999 | A |
5980550 | Eder | Nov 1999 | A |
5980554 | Lenker et al. | Nov 1999 | A |
5990237 | Bentley et al. | Nov 1999 | A |
6015431 | Thornton et al. | Jan 2000 | A |
6036720 | Abrams et al. | Mar 2000 | A |
6053940 | Wijay | Apr 2000 | A |
6060534 | Ronan et al. | May 2000 | A |
6063070 | Eder et al. | May 2000 | A |
6063111 | Hieshima et al. | May 2000 | A |
6086577 | Ken et al. | Jul 2000 | A |
6090911 | Petka et al. | Jul 2000 | A |
6093199 | Brown et al. | Jul 2000 | A |
6113629 | Ken | Sep 2000 | A |
6120847 | Yang et al. | Sep 2000 | A |
6140127 | Sprague | Oct 2000 | A |
6143022 | Shull et al. | Nov 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6165193 | Greene, Jr. et al. | Dec 2000 | A |
6165194 | Denardo et al. | Dec 2000 | A |
6168592 | Kupiecki et al. | Jan 2001 | B1 |
6168615 | Ken et al. | Jan 2001 | B1 |
6176240 | Nikolchev et al. | Jan 2001 | B1 |
6177095 | Sawhney et al. | Jan 2001 | B1 |
6184266 | Ronan et al. | Feb 2001 | B1 |
6187370 | Dinh et al. | Feb 2001 | B1 |
6190402 | Horton et al. | Feb 2001 | B1 |
6193708 | Ken et al. | Feb 2001 | B1 |
6201065 | Pathak et al. | Mar 2001 | B1 |
6221099 | Andersen et al. | Apr 2001 | B1 |
6224892 | Searle | May 2001 | B1 |
6231597 | Deem | May 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6264695 | Stoy | Jul 2001 | B1 |
6268161 | Han et al. | Jul 2001 | B1 |
6273908 | Ndondo-Lay | Aug 2001 | B1 |
6280457 | Wallace et al. | Aug 2001 | B1 |
6287318 | Villar | Sep 2001 | B1 |
6287333 | Appling et al. | Sep 2001 | B1 |
6309367 | Boock | Oct 2001 | B1 |
6360129 | Ley et al. | Mar 2002 | B1 |
6364893 | Sahatjian et al. | Apr 2002 | B1 |
6383174 | Eder | May 2002 | B1 |
6398808 | Palasis | Jun 2002 | B1 |
6419686 | McLeod et al. | Jul 2002 | B1 |
6551303 | Van Tassel et al. | Apr 2003 | B1 |
6554849 | Jones et al. | Apr 2003 | B1 |
6569179 | Teoh et al. | May 2003 | B2 |
6569190 | Whalen, II et al. | May 2003 | B2 |
6582460 | Cryer | Jun 2003 | B1 |
6596296 | Nelson et al. | Jul 2003 | B1 |
6605111 | Bose et al. | Aug 2003 | B2 |
6605294 | Sawhney | Aug 2003 | B2 |
6613073 | White et al. | Sep 2003 | B1 |
6613074 | Mitelberg et al. | Sep 2003 | B1 |
6663607 | Slaikeu et al. | Dec 2003 | B2 |
6712836 | Berg et al. | Mar 2004 | B1 |
6716445 | Won et al. | Apr 2004 | B2 |
6723108 | Jones et al. | Apr 2004 | B1 |
6746468 | Sepetka et al. | Jun 2004 | B1 |
6748953 | Sherry et al. | Jun 2004 | B2 |
6786876 | Cox | Sep 2004 | B2 |
6811560 | Jones et al. | Nov 2004 | B2 |
6818013 | Mitelberg et al. | Nov 2004 | B2 |
6878384 | Cruise et al. | Apr 2005 | B2 |
6932833 | Sandoval et al. | Aug 2005 | B1 |
7018403 | Pienknagura | Mar 2006 | B1 |
7037331 | Mitelberg et al. | May 2006 | B2 |
7195648 | Jones et al. | Mar 2007 | B2 |
7241301 | Thramann | Jul 2007 | B2 |
7300661 | Henson et al. | Nov 2007 | B2 |
7311726 | Mitelberg et al. | Dec 2007 | B2 |
7361367 | Henson et al. | Apr 2008 | B2 |
7371228 | Chu et al. | May 2008 | B2 |
7396540 | Chu et al. | Jul 2008 | B2 |
7442382 | Henson et al. | Oct 2008 | B2 |
7481821 | Fogarty | Jan 2009 | B2 |
7517361 | Ravenscroft | Apr 2009 | B1 |
7530988 | Evans et al. | May 2009 | B2 |
7569066 | Gerberding et al. | Aug 2009 | B2 |
7572288 | Cox | Aug 2009 | B2 |
7582109 | Delegge | Sep 2009 | B2 |
7666220 | Evans et al. | Feb 2010 | B2 |
7790273 | Lee et al. | Sep 2010 | B2 |
7815661 | Mirizzi et al. | Oct 2010 | B2 |
7862538 | Sawhney et al. | Jan 2011 | B2 |
7951448 | Lee et al. | May 2011 | B2 |
7959676 | Thramann et al. | Jun 2011 | B2 |
8048145 | Evans et al. | Nov 2011 | B2 |
8075585 | Lee et al. | Dec 2011 | B2 |
8105352 | Egnelov | Jan 2012 | B2 |
8182525 | Herbowy et al. | May 2012 | B2 |
8231666 | Kim et al. | Jul 2012 | B2 |
8231890 | Cruise et al. | Jul 2012 | B2 |
8252040 | Cox | Aug 2012 | B2 |
8262686 | Fogarty | Sep 2012 | B2 |
8317799 | Schon | Nov 2012 | B2 |
8333798 | Gandhi et al. | Dec 2012 | B2 |
8465779 | Cruise et al. | Jun 2013 | B2 |
8486046 | Hayman et al. | Jul 2013 | B2 |
8535367 | Kim et al. | Sep 2013 | B2 |
8562341 | Luebke | Oct 2013 | B2 |
8562636 | Fogarty | Oct 2013 | B2 |
8562643 | Tekulve et al. | Oct 2013 | B2 |
8562662 | Kim et al. | Oct 2013 | B2 |
8585723 | Nardone et al. | Nov 2013 | B2 |
8597674 | Chu et al. | Dec 2013 | B2 |
8636764 | Miles et al. | Jan 2014 | B2 |
8647377 | Kim et al. | Feb 2014 | B2 |
20010000188 | Lenker et al. | Apr 2001 | A1 |
20010000797 | Mazzocchi et al. | May 2001 | A1 |
20010012961 | Deem | Aug 2001 | A1 |
20010025195 | Shaolian et al. | Sep 2001 | A1 |
20010047202 | Slaikeu | Nov 2001 | A1 |
20020013618 | Marotta | Jan 2002 | A1 |
20020026228 | Schauerte | Feb 2002 | A1 |
20020026232 | Marotta | Feb 2002 | A1 |
20020049495 | Kutryk | Apr 2002 | A1 |
20020052648 | Mcguckin | May 2002 | A1 |
20020123789 | Francis | Sep 2002 | A1 |
20020143349 | Gifford et al. | Oct 2002 | A1 |
20020169473 | Sepetka et al. | Nov 2002 | A1 |
20030004531 | Jones | Jan 2003 | A1 |
20030018294 | Cox | Jan 2003 | A1 |
20030023190 | Cox | Jan 2003 | A1 |
20030055451 | Jones | Mar 2003 | A1 |
20030120300 | Porter | Jun 2003 | A1 |
20030135266 | Chew et al. | Jul 2003 | A1 |
20030135267 | Solem | Jul 2003 | A1 |
20030139802 | Wulfman | Jul 2003 | A1 |
20030139806 | Haverkost et al. | Jul 2003 | A1 |
20030171739 | Murphy | Sep 2003 | A1 |
20040034386 | Fulton | Feb 2004 | A1 |
20040044351 | Searle | Mar 2004 | A1 |
20040087998 | Lee et al. | May 2004 | A1 |
20040093076 | White | May 2004 | A1 |
20040098027 | Teoh et al. | May 2004 | A1 |
20040106945 | Thramann | Jun 2004 | A1 |
20040111112 | Hoffmann | Jun 2004 | A1 |
20040172056 | Guterman | Sep 2004 | A1 |
20040186562 | Cox | Sep 2004 | A1 |
20040193206 | Gerberding | Sep 2004 | A1 |
20050033409 | Burke | Feb 2005 | A1 |
20050090856 | Porter | Apr 2005 | A1 |
20050283962 | Boudjemline | Dec 2005 | A1 |
20060009798 | Callister et al. | Jan 2006 | A1 |
20060052820 | Haig | Mar 2006 | A1 |
20060122685 | Bonsignore et al. | Jun 2006 | A1 |
20060206201 | Garcia et al. | Sep 2006 | A1 |
20070078479 | Belenkaya et al. | Apr 2007 | A1 |
20070148243 | Bates | Jun 2007 | A1 |
20070179590 | Lu et al. | Aug 2007 | A1 |
20070207186 | Scanlon et al. | Sep 2007 | A1 |
20070227544 | Swann et al. | Oct 2007 | A1 |
20070276465 | Mongrain | Nov 2007 | A1 |
20070276470 | Tenne | Nov 2007 | A1 |
20070299464 | Cruise et al. | Dec 2007 | A1 |
20080109063 | Hancock et al. | May 2008 | A1 |
20080208167 | Stankus | Aug 2008 | A1 |
20080221671 | Chouinard et al. | Sep 2008 | A1 |
20090056722 | Swann | Mar 2009 | A1 |
20090099643 | Hyodoh et al. | Apr 2009 | A1 |
20090177221 | Kramann | Jul 2009 | A1 |
20090177264 | Ravenscroft | Jul 2009 | A1 |
20090182371 | Clausen et al. | Jul 2009 | A1 |
20090198315 | Boudjemline | Aug 2009 | A1 |
20090232869 | Greene, Jr. | Sep 2009 | A1 |
20090254176 | Butera | Oct 2009 | A1 |
20090287145 | Cragg et al. | Nov 2009 | A1 |
20090287297 | Cox | Nov 2009 | A1 |
20090287300 | Dave et al. | Nov 2009 | A1 |
20100262177 | Frigstad et al. | Oct 2010 | A1 |
20110066221 | White et al. | Mar 2011 | A1 |
20110245802 | Hayman et al. | Oct 2011 | A1 |
20120095501 | Nardone et al. | Apr 2012 | A1 |
20120101519 | Hill et al. | Apr 2012 | A1 |
20120118445 | Luebke | May 2012 | A1 |
20120271348 | Tekulve | Oct 2012 | A1 |
20120272526 | Luebke | Nov 2012 | A1 |
Number | Date | Country |
---|---|---|
0107055 | May 1984 | EP |
0441516 | Aug 1991 | EP |
0518704 | Dec 1992 | EP |
0627201 | Dec 1994 | EP |
0664104 | Jul 1995 | EP |
0717969 | Jun 1996 | EP |
1266631 | Dec 2002 | EP |
1691881 | May 2005 | EP |
1732467 | Dec 2006 | EP |
2105110 | Sep 2009 | EP |
2139898 | Nov 1984 | GB |
WO1989011257 | Nov 1989 | WO |
WO1992014408 | Aug 1992 | WO |
WO1994016629 | Aug 1994 | WO |
WO1995018585 | Jul 1995 | WO |
WO1995032018 | Nov 1995 | WO |
WO1997042910 | Nov 1997 | WO |
WO1998004198 | Feb 1998 | WO |
WO1998050102 | Nov 1998 | WO |
WO1998058590 | Dec 1998 | WO |
WO1999002092 | Jan 1999 | WO |
WO1999005977 | Feb 1999 | WO |
WO1999007293 | Feb 1999 | WO |
WO1999059479 | Nov 1999 | WO |
WO1999062429 | Dec 1999 | WO |
WO1999062432 | Dec 1999 | WO |
WO1999065397 | Dec 1999 | WO |
WO2000004845 | Feb 2000 | WO |
WO2000007524 | Feb 2000 | WO |
WO2000013593 | Mar 2000 | WO |
WO2000018321 | Apr 2000 | WO |
WO2000027292 | May 2000 | WO |
WO2000032112 | Jun 2000 | WO |
WO2000044306 | Aug 2000 | WO |
WO2000056247 | Sep 2000 | WO |
WO2000057818 | Oct 2000 | WO |
WO2000062711 | Oct 2000 | WO |
WO2000074577 | Dec 2000 | WO |
WO2001001890 | Jan 2001 | WO |
WO2001003607 | Jan 2001 | WO |
WO2001037892 | May 2001 | WO |
WO2001041676 | Jun 2001 | WO |
WO2001093780 | Dec 2001 | WO |
WO2002005731 | Jan 2002 | WO |
WO2002080782 | Oct 2002 | WO |
WO2002087472 | Nov 2002 | WO |
WO2003077984 | Sep 2003 | WO |
WO2006081407 | Aug 2006 | WO |
WO2007028452 | Mar 2007 | WO |
WO2007062661 | Jun 2007 | WO |
WO2008115922 | Sep 2008 | WO |
WO2009003049 | Dec 2008 | WO |
WO2009096991 | Aug 2009 | WO |
WO2009132141 | Oct 2009 | WO |
WO2011084536 | Jul 2011 | WO |
WO2013184595 | Dec 2013 | WO |
Entry |
---|
WIPO, International Preliminary Examining Authority (U.S. Patent and Trademark Office), International Preliminary Report on Patentability dated Nov. 21, 2013 in International Patent Application No. PCT/US2012/037621, 7 pages. |
Balt Extrusion, Montmorency, Francy, “LEO+,” Intracranial self expandable stent and delivery system, product page. |
WIPO, U.S. International Search Authority, International Search Report and Written Opinion dated Oct. 22, 2012 in International Patent Application No. PCT/US2012/037621, 10 pages. |
WIPO, U.S. International Search Authority, International Search Report and Written Opinion dated Mar. 7, 2011 in International Patent Application No. PCT/US2010/061627, 9 pages. |
Han, Y.M. et al., “Flared Polyurethane-covered Self-expandable Nitinol Stent for Malignant Biliary Obstruction,” J Vase Interv Radiol, Oct. 2003; 14 (10): pp. 1291-1301. |
Lieber, B.B. et al., “Alteration of Hemodynamics in Aneurysm Models by Stenting. Influence of Stent Porosity,” Annals of Biomedical Engineering, 1997, vol. 25, pp. 460-469. |
Duprat G. Jr., et al., “Self Expanding Evaluation”, Radiology 1987; 162: 469-472. |
Guglielmi G., et al., “Electrothrombosis of Results”, J. Neurosurg. 1991; 75: 1-7. |
Guglielmi G., et al., “Electrothrombosis of saccular aneurysms via endovascular approach”, J. Neurosurg. 1991; 75: 8-14. |
Hieshima G. B. et al., “A Detachable Occlusion”, Radiology 1981; 138: 227-228. |
Paper No. 199, American Society of Neuroradiology, 29th Annual Meeting, Washington, D.C., Jun. 9-14, 1991. |
Paper No. 200, American Society of Neuroradiology, 29th Annual Meeting, Washington, D.C., Jun. 9-14, 1991. |
Romodanov A. P., et al., Intravascular Occlusion Catheter, In Advances & Technical Standards, vol. 9, 1982; 25 49. |
Serbinenko F. A. “Balloon Catheterization and Cerebral Vessels”, J. Neurosurg. 1974; 41: 125-145. |
Sigwart V., et al., Intravascular Angioplasty, N. England J. Med., 1987; 316: 701 706. |
Strecker E. P., “Flexible, Balloon Results”, Radiology 1988; 169: 388. |
Ahuja, A.A., Hergenrother, R. W., Strother, C.M., Rappe, A.A., Cooper, S.L., and Graves, V.B., “Platinum Coil Coatings to Increase Thrombogenicity: A Preliminary Study in Rabbits,” AJNR 14:794-798, Jul./Aug. 1993. |
Dawson, R., M.D., Krisht, A., M.D., Barrow, D., M.D., Joseph, G., M.D., Shengelaia, G., M.D., and Bonner, G., M.B.A., “Treatment of Experimental Aneurysms Using Collagen-Coated Microcoils,” Neurosurgery, 36:133-140, 1995. |
Vinuela, F., M.D., Duckwiler, G., M.D., and Mawad, M., M.D., “Guglielmi Detachable Coil Emoblization of Acute Intracranial Aneurysm: Perioperative Anatomical and Clinical Outcome in 403 Patients,” J. Neurosurg 86:475-482, 1997. |
Number | Date | Country | |
---|---|---|---|
20120316597 A1 | Dec 2012 | US |
Number | Date | Country | |
---|---|---|---|
61485065 | May 2011 | US |